HK1211293A1 - 布魯頓氏酪氨酸激酶抑制劑 - Google Patents

布魯頓氏酪氨酸激酶抑制劑

Info

Publication number
HK1211293A1
HK1211293A1 HK15112141.6A HK15112141A HK1211293A1 HK 1211293 A1 HK1211293 A1 HK 1211293A1 HK 15112141 A HK15112141 A HK 15112141A HK 1211293 A1 HK1211293 A1 HK 1211293A1
Authority
HK
Hong Kong
Prior art keywords
tyrosine kinase
kinase inhibitors
brutons tyrosine
brutons
inhibitors
Prior art date
Application number
HK15112141.6A
Other languages
English (en)
Inventor
‧施普林格
‧戴瓦達斯
‧加蘭
‧格拉佩豪斯
‧韓
‧霍克曼
‧休斯
‧薩亞
‧施努特
‧賽爾內斯
‧沃克
‧萬
‧邢
‧查普夫
‧施密特
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HK1211293A1 publication Critical patent/HK1211293A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112141.6A 2012-11-02 2015-12-09 布魯頓氏酪氨酸激酶抑制劑 HK1211293A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04
PCT/IB2013/059846 WO2014068527A1 (en) 2012-11-02 2013-11-01 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1211293A1 true HK1211293A1 (zh) 2016-05-20

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112141.6A HK1211293A1 (zh) 2012-11-02 2015-12-09 布魯頓氏酪氨酸激酶抑制劑

Country Status (27)

Country Link
US (4) US20150291554A1 (zh)
EP (1) EP2914586B1 (zh)
JP (1) JP6178861B2 (zh)
KR (1) KR101668574B1 (zh)
CN (1) CN105008344B (zh)
AP (1) AP2015008381A0 (zh)
AU (1) AU2013340345B2 (zh)
BR (1) BR112015009624A2 (zh)
CA (1) CA2888960C (zh)
CL (1) CL2015001168A1 (zh)
CO (1) CO7350624A2 (zh)
CR (1) CR20150228A (zh)
DO (1) DOP2015000100A (zh)
EA (1) EA201500393A1 (zh)
ES (1) ES2625944T3 (zh)
GE (1) GEP201606597B (zh)
HK (1) HK1211293A1 (zh)
IL (1) IL238571A0 (zh)
MD (1) MD20150035A2 (zh)
MX (1) MX2015005422A (zh)
NI (1) NI201500059A (zh)
PE (1) PE20151070A1 (zh)
PH (1) PH12015500940A1 (zh)
SG (1) SG11201502893WA (zh)
TN (1) TN2015000168A1 (zh)
TW (1) TWI518080B (zh)
WO (1) WO2014068527A1 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
MX361815B (es) 2012-09-10 2018-12-17 Principia Biopharma Inc Compuestos pirazolopirimidinicos como inhibidores de cinasas.
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
BR112015021856A2 (pt) * 2013-03-15 2017-07-18 Janssen Pharmaceutica Nv processos e intermediários para a preparação de um medicamento
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
EP3736015B1 (en) * 2013-08-19 2023-06-28 TARIS Biomedical LLC Multi-unit drug delivery devices
KR102272792B1 (ko) 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
WO2016100914A1 (en) 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
JP6891173B2 (ja) * 2015-11-17 2021-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いたｍｓの治療方法
CN114591242A (zh) * 2015-12-16 2022-06-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
MY197440A (en) 2015-12-16 2023-06-19 Boehringer Ingelheim Int Heteroamatic compounds as btk inhibitors
EP3402789B1 (en) 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
AU2017265219B2 (en) * 2016-05-16 2021-02-04 Evopoint Biosciences Co., Ltd. 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
IL272838B2 (en) 2017-10-06 2023-09-01 Forma Therapeutics Inc Peptidase-specific ubiquitin inhibition 30
WO2019091441A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
CN111225669B (zh) * 2017-11-10 2020-12-29 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
PE20211053A1 (es) 2018-10-05 2021-06-07 Forma Therapeutics Inc Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30)
JP7204005B2 (ja) * 2019-03-14 2023-01-13 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
BR112021022646A2 (pt) * 2019-05-21 2022-03-29 Janssen Pharmaceutica Nv Processos e intermediários para a preparação de um inibidor de btk
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023284765A1 (zh) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023150663A1 (en) * 2022-02-04 2023-08-10 Retune Pharma Inc. Certain chemical entities, compositions, and methods
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途
WO2024153226A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
JP2009536617A (ja) 2006-04-11 2009-10-15 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
CA2692713A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
EA019722B1 (ru) 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
TWI711610B (zh) * 2009-09-04 2020-12-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
MX2015001802A (es) * 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN115155188A (zh) 2014-04-09 2022-10-11 唐纳森公司 自承式折叠的片材材料以及过滤元件
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
GEP201606597B (en) 2017-01-10
AP2015008381A0 (en) 2015-04-30
AU2013340345A1 (en) 2015-04-30
EA201500393A1 (ru) 2016-05-31
CR20150228A (es) 2015-09-14
US10266513B2 (en) 2019-04-23
CO7350624A2 (es) 2015-08-10
TW201431851A (zh) 2014-08-16
US20170283393A1 (en) 2017-10-05
BR112015009624A2 (pt) 2017-11-14
NI201500059A (es) 2015-06-05
ES2625944T3 (es) 2017-07-21
CN105008344A (zh) 2015-10-28
CL2015001168A1 (es) 2015-07-10
TWI518080B (zh) 2016-01-21
IL238571A0 (en) 2015-06-30
KR101668574B1 (ko) 2016-10-24
PE20151070A1 (es) 2015-08-01
JP2015535277A (ja) 2015-12-10
EP2914586A1 (en) 2015-09-09
JP6178861B2 (ja) 2017-08-09
CA2888960C (en) 2017-08-15
US20210002251A1 (en) 2021-01-07
US10815213B2 (en) 2020-10-27
KR20150075114A (ko) 2015-07-02
MD20150035A2 (ro) 2015-10-31
EP2914586B1 (en) 2017-04-05
DOP2015000100A (es) 2015-12-31
PH12015500940A1 (en) 2015-06-29
TN2015000168A1 (fr) 2016-10-03
CA2888960A1 (en) 2014-05-08
CN105008344B (zh) 2017-07-25
MX2015005422A (es) 2015-08-05
US20150291554A1 (en) 2015-10-15
AU2013340345B2 (en) 2016-10-27
WO2014068527A1 (en) 2014-05-08
US20190202798A1 (en) 2019-07-04
SG11201502893WA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
HK1211293A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1210775A1 (zh) 作為激酶抑制劑的咪唑並三嗪甲腈
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基－苯並噻唑酮
HK1210161A1 (zh) 用作布魯頓酪氨酸激酶 抑制劑的雜芳族化合物
HK1194381A1 (zh) 酪氨酸激酶抑制劑
HK1197060A1 (zh) 酪氨酸激酶抑制劑
PT2710005T (pt) Inibidores de tirosina-quinase
HK1210779A1 (zh) 酪氨酸激酶抑制劑
HK1210461A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1206624A1 (zh) 用於造血動員的布魯頓酪氨酸激酶抑制劑
EP2917210A4 (en) KINASE INHIBITORS
HK1209277A1 (zh) -三嗪- -甲酰胺激酶抑制劑
HK1200816A1 (zh) 布魯頓酪氨酸激酶抑制劑
EP2934525A4 (en) THIAZOLSUBSTITUTED AMINOPYRIDINE AS MILTSTYROSINKINASE INHIBITOR
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2903970A4 (en) SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1209316A1 (zh) 取代的吡啶酰胺激酶抑制劑